FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma.

Thomas M Anderson Bryan H Chang Alexander C Huang George X Xu Daniel Yoon Catherine G Shang Rosemarie Mick Erin Schubert Suzanne McGettigan Kristin Kreider Wei Xu E John Wherry Lynn M Schuchter Ravi K Amaravadi Tara C Mitchell Michael D Farwell

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Early FDG PET/CT can identify metabolic changes in melanoma metastases that are potentially predictive of response to pembrolizumab and significantly correlated with PFS.

Keyphrases

advanced non small cell lung cancer
skin cancer
high resolution
basal cell carcinoma
randomized controlled trial
clinical trial
photodynamic therapy
fluorescence imaging
double blind